Hyperion DeFi, Inc. Common Stock (HYPD) Stock Price

HYPDStock

$2.84−58.30%52W

Market Cap$43.17M

P/E—

PEG Ratio—

Div yield—

Beta2.64

HYPD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.13%

Price vs S&P 500 (4W)-24.91%

VGM Score58.23

Book Value / Share (Quarterly)$6.66

P/TBV (Annual)1.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-84.00%

Cash Flow / Share (Quarterly)$-5.61

Price vs S&P 500 (YTD)-32.15%

Gross Margin (TTM)78.35%

Net Profit Margin (TTM)474.87%

EPS (TTM)$-2.10

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$-2.10

Revenue Growth (5Y)-16.47%

EPS (Annual)$-9.06

Dividend / Share (Annual)$0.18

ROI (Annual)-92.75%

Gross Margin (Annual)62.72%

Net Profit Margin (5Y Avg)-162564.62%

Cash / Share (Quarterly)$0.63

P/E Basic Excl Extra (TTM)6.63x

Revenue Growth QoQ (YoY)1559.44%

ROA (Last FY)-87.54%

Revenue Growth TTM (YoY)1455.11%

EBITD / Share (TTM)$0.40

ROE (5Y Avg)-153.50%

Operating Margin (TTM)474.61%

Cash Flow / Share (Annual)$-9.99

P/B Ratio0.43x

P/B Ratio (Quarterly)0.47x

Net Income / Employee (Annual)$-5,034,900

EV / Revenue (TTM)30.65x

Net Interest Coverage (TTM)-21.36x

ROA (TTM)8.37%

EV / EBITDA (TTM)6.41x

EPS Incl Extra (Annual)$-9.06

Current Ratio (Annual)2.68x

Quick Ratio (Quarterly)1.86x

3-Month Avg Trading Volume0.50M

52-Week Price Return-58.30%

P/E Incl Extra (TTM)6.63x

Revenue / Employee (TTM)$155,600

Tangible BV / Share (Quarterly)$4.98

P/S Ratio (Annual)54.25x

Asset Turnover (Annual)0.02x

52-Week High$9.13

Operating Margin (5Y Avg)-152377.62%

EPS Excl Extra (Annual)$-9.06

CapEx CAGR (5Y)207.90%

26-Week Price Return-20.22%

Quick Ratio (Annual)2.56x

13-Week Price Return3.65%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)2.34x

Enterprise Value$42.93M

Revenue / Share Growth (5Y)11.36%

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$90,400

Pretax Margin (Annual)-5570.58%

Cash / Share (Annual)$0.74

3-Month Return Std Dev82.60%

Gross Margin (5Y Avg)-1307.55%

Net Income / Employee (TTM)$739,100

ROE (Last FY)-110.36%

Net Interest Coverage (Annual)-1.94x

EPS Basic Excl Extra (Annual)$-9.06

Total Debt / Equity (Quarterly)0.08x

EPS Incl Extra (TTM)$-2.10

ROI (TTM)8.73%

P/S Ratio (TTM)31.51x

Pretax Margin (5Y Avg)-162564.62%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$2.36

Forward P/E18.07x

Price vs S&P 500 (52W)-73.83%

P/E Ratio (TTM)6.63x

Year-to-Date Return-20.22%

5-Day Price Return-18.16%

EPS Normalized (Annual)$-9.06

ROA (5Y Avg)-334.23%

Net Profit Margin (Annual)-5570.58%

Month-to-Date Return-24.17%

EBITD / Share (Annual)$-8.87

Operating Margin (Annual)-5456.49%

LT Debt / Equity (Annual)0.19x

ROI (5Y Avg)-97.89%

P/E Excl Extra (TTM)6.63x

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-2.10

P/TBV (Quarterly)0.62x

P/B Ratio (Annual)0.71x

Inventory Turnover (TTM)0.42x

Pretax Margin (TTM)474.87%

Book Value / Share (Annual)$4.73

Price vs S&P 500 (13W)0.96%

Beta2.64x

Revenue / Share (TTM)$0.08

ROE (TTM)9.77%

52-Week Low$2.34

vGradeC

gGradeB

mGradeC

vgmGradeC

HYPD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	$2.24	$0.92	-58.93%(-$1.32)
Q4 2025	Mar 26, 2026	-$4.62	-$6.29	-36.15%(-$1.67)
Q3 2025	Nov 13, 2025	—	$0.05	—

HYPD Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HYPDHyperion DeFi, Inc. Common Stock	C	B	C	31.5x	1455.1%	78.3%	—	$2.84
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Hyperion DeFi, Inc. Common Stock

Eyenovia is a clinical-stage ophthalmic company developing novel treatments using its proprietary microarray print (MAP) platform and Optejet delivery system—a precision-targeted alternative to conventional eye droppers. The company's pipeline aims to improve drug safety, tolerability, patient compliance, and therapeutic efficacy across multiple eye disease indications. Eyenovia's smart ophthalmic therapies leverage novel formulations and drug combinations powered by its targeted delivery technology.